Get all premium features to the best stock analysis tool

Champions Oncology Reports Revenue of $16.6 Million

Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026. Third Quarter and Recent Highlights: Record study service revenue of $16.6 million, up approximately 32% year over year Total revenue of $16.6 million, compared to $17.0 million in the prior-year period Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000 The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work.

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025. Second Quarter and Recent Highlights: Total revenue increased 11% to $15 million Oncology services profit of $7.8 million; oncology services margin of 52% Net income of $237,000 Adjusted EBITDA of $843,000 First Half 2026 Highlights: Total revenue increased 5% to $29 million Oncology services profit of $13.8 million; oncology services margin of 47% Adjusted EBITDA of $962,000 Robert Brainin, CEO of Champions, commented, "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress.

Champions Oncology Reports Record Annual Revenue of $57 Million

Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025. Fourth Quarter Financial Highlights: Total revenue of $12.3 million Adjusted EBITDA loss of $1.2 million New data licensing revenue of approximately $200,000 Operating cash flow of $6.4 million Fiscal Year 2025 Financial Highlights: Record annual revenue of $57 million, an increase of 14% year-over-year Net income of $4.6 million Adjusted EBITDA income of $7.1 million Data license revenue of $4.7 million Year-end cash balance of $9.8 million Ronnie Morris, CEO of Champions, commented, "This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation".

Champions Oncology Announces Appointment of New CEO

HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025. Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017.